Phaarmasia Intrinsic Value
Phaarmasia intrinsic value. Phaarmasia (PHRMASI) median intrinsic value is ₹184.80 from 9 valuation models (range ₹63–₹277), vs current price ₹92.40 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Compare with PHRMASI fair value estimate to assess whether the stock is under or overvalued.
PHRMASI Valuation Methods Summary — DCF, Graham Number & P/E
Phaarmasia intrinsic value across 9 models vs current price ₹92.40 — upside/downside and value range per method. For current market price and key ratios, visit Phaarmasia screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹277.20 | ₹221.76 - ₹332.64 | +200.0% | EPS: ₹25.80, Sector P/E: 22x |
| Book Value Method | asset | ₹62.86 | ₹56.57 - ₹69.15 | -32.0% | Book Value/Share: ₹31.43, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹184.80 | ₹166.32 - ₹203.28 | +100.0% | Revenue/Share: ₹98.57, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹184.80 | ₹166.32 - ₹203.28 | +100.0% | EBITDA: ₹22.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹231.00 | ₹184.80 - ₹277.20 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹165.12 | ₹148.61 - ₹181.63 | +78.7% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹277.20 | ₹249.48 - ₹304.92 | +200.0% | Revenue Growth: 15.0%, Adj P/E: 16.1x |
| ROE Based Valuation | profitability | ₹184.80 | ₹166.32 - ₹203.28 | +100.0% | ROE: 81.8%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹62.86 | ₹56.57 - ₹69.15 | -32.0% | EPS: ₹25.80, BVPS: ₹31.43 |
PHRMASI Intrinsic Value vs Market Price — All Valuation Models
Phaarmasia fair value range ₹63–₹277 vs current market price ₹92.40 across 9 valuation models. Read PHRMASI dividend payout details for the complete payout history and dividend yield track record.
PHRMASI Intrinsic Value Analysis — Undervalued or Overvalued?
Phaarmasia median intrinsic value ₹184.80, current price ₹92.40 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of PHRMASI?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Phaarmasia (PHRMASI) is ₹184.80 (median value). With the current market price of ₹92.40, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹62.86 to ₹277.20, indicating ₹62.86 - ₹277.20.
Is PHRMASI undervalued or overvalued?
Based on our multi-method analysis, Phaarmasia (PHRMASI) appears to be trading below calculated value by approximately 100.0%.
PHRMASI Financial Health — Key Ratios vs Industry Benchmarks
Phaarmasia financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 81.8% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 2.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 2.30x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
PHRMASI Cash Flow Quality — Operating & Free Cash Flow
Phaarmasia operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹22 Cr | ₹16 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |